Pharma split: The Tipline for 18 November 2019

18 November 2019

We had a split decision at the Federal Trade Commission. The agency voted 3-2 to order drugmakers Bristol-Myers Squibb and Celgene divest psoriasis drug Otezla as a condition for the companies’ proposed $13.4 billion merger. Commissioners Rohit Chopra and Rebecca Slaughter offered dissenting opinions, arguing a “status quo” merger analysis is not enough to address all the potential harms of the deal.